Table 3.
Results of separate subgroups of group B before and six months after initiation of treatment; mean number of affected peripheral (PS) and central segments (CS) of neovascularization; corrected distance visual acuity (CDVA).
| 6 months after treatment (1 month in group 4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| CDVA | PS | CS | CDVA | PS | CS | P | ||
| 1 | Pterygium (n = 12) | 1.0 (±0.02) | 12.75 (±9.91) | 0.25 (±0.82) | 1.0 (±0.02) | 9.0 (±4.08) | 0 | PS: 0.003 |
| CS: 0.000 | ||||||||
|
| ||||||||
| 2 | NV after penetrating keratoplasty (n = 6) | 0.06 (±0.04) | 35.5 (±20.13) | 0.83 (±1.21) | 0.12 (±0.13) | 28.0 (±23.12) | 0.33 (±0.74) | PS: 0.002 |
| CS: 0.000 | ||||||||
|
| ||||||||
| 3 | Other etiologies (n = 15) | 0.58 (±0.32) | 37.0 (±21.49) | 3.4 (±4.01) | 0.59 (±0.32) | 29.53 (±18.73) | 2.53 (±3.98) | PS: 0.000 |
| CS: 0.000 | ||||||||
|
| ||||||||
| 4 | Preparation for penetrating keratoplasty (n = 5) | 0.05 (±0.07) | 28.2 (±12.37) | 10.8 (±6.65) | 0.05 (±0.08) | 20.40 (±14.25) | 6.0 (±5.62) | PS: 0.02 |
| CS: 0.001 | ||||||||